Dawn L. Hershman, MD, MS (IMAGE)
Caption
Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors for breast cancer are at significantly higher risk of stopping that therapy early (non-adherence).
“We recognize that non-adherence to endocrine therapy is multifactorial. Predicting who is at risk will help us target personalized interventions to the right patients,” said Hershman, who is American Cancer Society Professor of Medicine and Epidemiology at Columbia University Irving Medical Center, deputy director of the Herbert Irving Comprehensive Cancer Center, and group co-chair-elect of SWOG Cancer Research Network.
Credit
SWOG/Hope Foundation
Usage Restrictions
Credit must be given to the creator.
License
CC BY